Status:
COMPLETED
Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy
Lead Sponsor:
Eli Lilly and Company
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.
Eligibility Criteria
Inclusion
- Clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent
- Have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs).
- Tumors must not be positive for HER2, but if positive, the treatment plan should not include further treatment with the drug Herceptin.
- Disease that can be definitely measured on Cat Scans or other radiological tests.
- May have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study.
Exclusion
- More than 2 chemotherapy regimens for metastatic or locally recurrent disease.
- Have brain cancer from breast cancer
- Pregnant or breastfeeding
- Have an inability to swallow tablets
- Within 6 months have had a serious heart condition
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00386087
Start Date
November 1 2006
End Date
September 1 2007
Last Update
June 6 2008
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Newark, Delaware, United States, 19713
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Indianapolis, Indiana, United States, 46202
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
South Bend, Indiana, United States, 46601
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Boston, Massachusetts, United States, 02115